CA2598893C - Eml4-alk fusion gene - Google Patents

Eml4-alk fusion gene Download PDF

Info

Publication number
CA2598893C
CA2598893C CA 2598893 CA2598893A CA2598893C CA 2598893 C CA2598893 C CA 2598893C CA 2598893 CA2598893 CA 2598893 CA 2598893 A CA2598893 A CA 2598893A CA 2598893 C CA2598893 C CA 2598893C
Authority
CA
Canada
Prior art keywords
eml4
seq
polypeptide
polynucleotide
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA 2598893
Other languages
English (en)
French (fr)
Other versions
CA2598893A1 (en
Inventor
Hiroyuki Mano
Sadao Kuromitsu
Nobuaki Shindo
Takatoshi Soga
Takashi Furutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
CureGene KK
Original Assignee
Astellas Pharma Inc
CureGene KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, CureGene KK filed Critical Astellas Pharma Inc
Priority to ES07254044T priority Critical patent/ES2335368T3/es
Priority to ES09006058.3T priority patent/ES2515170T3/es
Priority to EP20070254044 priority patent/EP1914240B1/en
Priority to JP2007265917A priority patent/JP4303303B2/ja
Priority to AT07254044T priority patent/ATE450547T1/de
Priority to DE200760003543 priority patent/DE602007003543D1/de
Priority to EP20090006058 priority patent/EP2116553B1/en
Publication of CA2598893A1 publication Critical patent/CA2598893A1/en
Priority to JP2009035918A priority patent/JP5172736B2/ja
Application granted granted Critical
Publication of CA2598893C publication Critical patent/CA2598893C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2598893 2006-10-11 2007-08-24 Eml4-alk fusion gene Active CA2598893C (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES09006058.3T ES2515170T3 (es) 2006-10-11 2007-10-11 Gen de fusión EML4-ALK
EP20070254044 EP1914240B1 (en) 2006-10-11 2007-10-11 EML4-ALK fusion gene
JP2007265917A JP4303303B2 (ja) 2006-10-11 2007-10-11 Ｅｍｌ４−ａｌｋ融合遺伝子
AT07254044T ATE450547T1 (de) 2006-10-11 2007-10-11 Eml4-alk-fusionsgen
ES07254044T ES2335368T3 (es) 2006-10-11 2007-10-11 Gen de fusion eml4-alk.
DE200760003543 DE602007003543D1 (de) 2006-10-11 2007-10-11 EML4-ALK-Fusionsgen
EP20090006058 EP2116553B1 (en) 2006-10-11 2007-10-11 EML4-ALK fusion gene
JP2009035918A JP5172736B2 (ja) 2006-10-11 2009-02-18 Ｅｍｌ４−ａｌｋ融合遺伝子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006277718 2006-10-11
JP277718/2006 2006-10-11
JP120670/2007 2007-05-01
JP2007120670 2007-05-01

Publications (2)

Publication Number Publication Date
CA2598893A1 CA2598893A1 (en) 2008-04-11
CA2598893C true CA2598893C (en) 2012-04-10

Family

ID=39277176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2598893 Active CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene

Country Status (7)

Country Link
US (7) US7728120B2 (OSRAM)
EP (1) EP2116553B1 (OSRAM)
JP (2) JP4303303B2 (OSRAM)
AT (1) ATE450547T1 (OSRAM)
CA (1) CA2598893C (OSRAM)
DE (1) DE602007003543D1 (OSRAM)
ES (2) ES2335368T3 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US7700339B2 (en) * 2006-04-14 2010-04-20 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2016089B1 (en) * 2006-04-14 2014-01-15 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
JP2011511949A (ja) * 2008-02-12 2011-04-14 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ
JP2009219728A (ja) * 2008-03-18 2009-10-01 Daito Giken:Kk 遊技台
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2012526563A (ja) * 2009-05-15 2012-11-01 インサイト ジェネティクス インコーポレイテッド 癌を診断および治療するためのａｌｋの融合に関する方法および組成物
EP2487250A4 (en) 2009-10-06 2013-03-20 Fujirebio Kk METHOD FOR DETECTING FUSION GENES
US9175350B2 (en) * 2009-12-22 2015-11-03 Quest Diagnostics Investments Incorporated EML4-ALK translocations in lung cancer
WO2011102507A1 (ja) 2010-02-22 2011-08-25 富士レビオ株式会社 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
AR080913A1 (es) * 2010-04-16 2012-05-16 Response Genetics Cebadores, sondas, metodos y conjuntos de elementos para la deteccion de variantes de eml4- alk
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
JP5780527B2 (ja) * 2010-09-02 2015-09-16 学校法人 久留米大学 単分子ｄｎａから形成される環状ｄｎａの作成方法
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
DK2670401T3 (en) * 2011-02-02 2015-09-07 Novartis Ag Methods for using the ALK-inhibitors
US20140296181A1 (en) * 2011-04-07 2014-10-02 Coferon, Inc. Methods of modulating oncogenic fusion proteins
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9416358B2 (en) 2011-08-31 2016-08-16 Kurume University Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
JP2016510316A (ja) * 2012-12-21 2016-04-07 エピザイム，インコーポレイティド 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
MX2015010791A (es) 2013-02-22 2015-11-26 Hoffmann La Roche Metodos para tratar el cancer y prevenir la resistencia a farmacos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6534930B2 (ja) 2013-07-26 2019-06-26 公益財団法人がん研究会 Ｎｔｒｋ３融合体の検出法
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2015064620A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
US10048277B2 (en) 2014-01-24 2018-08-14 Japanese Foundation For Cancer Research Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
EP4397659A3 (en) 2014-04-25 2024-10-02 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
US10597725B2 (en) * 2014-09-01 2020-03-24 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
US10921311B2 (en) 2016-01-15 2021-02-16 Japanese Foundation For Cancer Research Fusions and method for detecting same
JP6740172B2 (ja) * 2017-05-02 2020-08-12 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2020006314A1 (en) * 2018-06-27 2020-01-02 City Of Hope Modification of small rnas for therapeutic uses
MX2020014262A (es) 2018-06-29 2021-03-25 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende un agente basico poco soluble.
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
CN118159274A (zh) 2021-10-28 2024-06-07 中外制药株式会社 糖浆剂
IL317839A (en) 2022-07-04 2025-02-01 Chugai Pharmaceutical Co Ltd Combination drug
JPWO2024048555A1 (OSRAM) 2022-08-30 2024-03-07

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043783D1 (de) 1999-11-11 2010-03-18 Astellas Pharma Inc Metalloprotease mit aggrecanase-aktivität
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
PL2287156T3 (pl) 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
EP2016089B1 (en) 2006-04-14 2014-01-15 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US7964710B2 (en) 2011-06-21
US20110230545A1 (en) 2011-09-22
JP2008295444A (ja) 2008-12-11
ES2335368T3 (es) 2010-03-25
CA2598893A1 (en) 2008-04-11
US9932589B2 (en) 2018-04-03
EP2116553A1 (en) 2009-11-11
US20100240673A1 (en) 2010-09-23
US9029521B2 (en) 2015-05-12
JP2009100783A (ja) 2009-05-14
JP5172736B2 (ja) 2013-03-27
DE602007003543D1 (de) 2010-01-14
US20080090776A1 (en) 2008-04-17
US7728120B2 (en) 2010-06-01
US20150184161A1 (en) 2015-07-02
US7605131B2 (en) 2009-10-20
EP2116553B1 (en) 2014-07-30
US8197818B2 (en) 2012-06-12
US20130158095A1 (en) 2013-06-20
ATE450547T1 (de) 2009-12-15
US20180066266A1 (en) 2018-03-08
ES2515170T3 (es) 2014-10-29
JP4303303B2 (ja) 2009-07-29
US20090099193A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
CA2598893C (en) Eml4-alk fusion gene
EP1914240B1 (en) EML4-ALK fusion gene
AU2020202555B2 (en) Novel fusion molecules and uses thereof
US20240094208A1 (en) MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
KR102106962B1 (ko) 신규 fgfr3 융합체
JP2009278982A (ja) 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
JPWO2012014795A1 (ja) 新規ｒｅｔ融合体の検出法
MX2012009784A (es) Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
KR102406334B1 (ko) Nras-돌연변이 암의 치료에서 사용하기 위한 egfr 억제제 및 mek 억제제의 조합물
JPWO2007026969A1 (ja) 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JP2014054185A (ja) 新規ｂｒａｆ融合体の検出法

Legal Events

Date Code Title Description
EEER Examination request